IDM Pharma, Inc. (NASDAQ:IDMI)
CAPS Rating:
A biopharmaceutical company focused on developing innovative products to treat and control cancer while maintaining the patient's quality of life.
Growing the love for investing
A biopharmaceutical company focused on developing innovative products to treat and control cancer while maintaining the patient's quality of life.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
But MTPPE, JUVANAN, is due for FDA panel review on 5/9/07. I believe that they will recommend approval. The stock should sell up big on this news, maybe 20+. It may cool a little after that, but maybe not. JUVANAN is MTPPE and showed a survival benefit with minimal and non serious side effects.
Since it is an injection to stimulate macrophage cells, it could be used for all cancers, not just osteosarcoma. The approval, if so, would be for osteosarcoma, about 1000 cases in the US per year.
This is very small, but off label is really very large. You don't hear much about this now since the FDA hasn't passed on Juvanan yet, and they don't like pre-approval speculation about off label use.
But it is my opinion that Junanan, if approved, will eventually be used off label and that it will prove to be useful in the treatment of virtually all cancers. This would be a home run.